NEW YORK (GenomeWeb News) – Cellectis bioresearch and Indian contract research organization Syngene International said today they will co-develop novel genetically customized cell lines.
The collaboration between the two companies will leverage Paris-based Cellectis bioresearch's genome customization technology and Syngene's biology platform and capabilities to develop recombinant and knock-out cell lines for oncology and ADME-Tox-based drug discovery research.
Financial and other terms of the deal were not disclosed.
"This new partnership with Syngene International will enable us to mobilize each organizations' expertise and know-how and create synergies that will deliver hundreds of engineered cell lines for drug discovery and functional genomics," Cellectis bioresearch CEO Marc Le Bozec, said in a statement.
Cellectis bioresearch is a subsidiary of Cellectis.